CN1709312A - Chinese medicine composition for treating nettle-rash and skin itch and its preparing method - Google Patents
Chinese medicine composition for treating nettle-rash and skin itch and its preparing method Download PDFInfo
- Publication number
- CN1709312A CN1709312A CN 200510012208 CN200510012208A CN1709312A CN 1709312 A CN1709312 A CN 1709312A CN 200510012208 CN200510012208 CN 200510012208 CN 200510012208 A CN200510012208 A CN 200510012208A CN 1709312 A CN1709312 A CN 1709312A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- group
- herba spirodelae
- light blue
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 208000003251 Pruritus Diseases 0.000 title claims abstract description 22
- 208000024780 Urticaria Diseases 0.000 title claims description 13
- 238000000034 method Methods 0.000 title description 2
- 239000006187 pill Substances 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 239000008187 granular material Substances 0.000 claims abstract description 6
- 239000007938 effervescent tablet Substances 0.000 claims abstract description 4
- 239000007901 soft capsule Substances 0.000 claims abstract description 4
- 239000003826 tablet Substances 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000000341 volatile oil Substances 0.000 claims description 13
- 238000010992 reflux Methods 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000000469 ethanolic extract Substances 0.000 claims description 4
- 238000003809 water extraction Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 239000006196 drop Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 2
- -1 oral liquor Substances 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 241000234282 Allium Species 0.000 abstract 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 abstract 1
- 241000209501 Spirodela Species 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 description 35
- 210000003491 skin Anatomy 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 230000008961 swelling Effects 0.000 description 12
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 238000001694 spray drying Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 230000002567 autonomic effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000006837 decompression Effects 0.000 description 5
- 239000003651 drinking water Substances 0.000 description 5
- 235000020188 drinking water Nutrition 0.000 description 5
- 229960001340 histamine Drugs 0.000 description 5
- 238000010025 steaming Methods 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 230000003266 anti-allergic effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 206010052568 Urticaria chronic Diseases 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 208000030961 allergic reaction Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000006757 chemical reactions by type Methods 0.000 description 3
- 208000024376 chronic urticaria Diseases 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 229960001660 histamine phosphate Drugs 0.000 description 3
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000004064 recycling Methods 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000002992 thymic effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 229960004754 astemizole Drugs 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 208000013219 diaphoresis Diseases 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical group N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229960003088 loratadine Drugs 0.000 description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000002568 urticarial effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 208000000104 Arthus reaction Diseases 0.000 description 1
- 241001407408 Berberis fortunei Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010048961 Localised oedema Diseases 0.000 description 1
- LTGPFZWZZNUIIK-LURJTMIESA-N Lysol Chemical compound NCCCC[C@H](N)CO LTGPFZWZZNUIIK-LURJTMIESA-N 0.000 description 1
- 244000137852 Petrea volubilis Species 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention discloses a Chinese medicine composition for effectively curing acute and chronic urticari and pruritus cutanea with obvious therapeutic effect. Said Chinese medicine composition can be made into granules preparation, cpsule, dripping pills, soft capsule, oral liquor, effervescent tablet, tablet, bolus and coated pills, and is made up by using the Chinese medicinal materials of spirodela and Chinese green onion through a certain preparation process.
Description
Technical field
What the present invention relates to is a kind of Chinese medicine composition and preparation method thereof, or rather, relates to a kind of Chinese medicine composition that is used for the treatment of urticaria and skin pruritus and preparation method thereof.
Background technology
Urticaria is the commonly encountered diseases in a kind of allergic skin disease, shows as the welt skin lesion appearing without definite location, the time time-out disappear, pruritus is immoderate, the complicated difficulty of the cause of disease is sought, and is easy to repeatedly, does not often touchingly heal, and is difficult to radical cure.Be mainly in the women clinically, especially with the young and the middle aged for seeing more.Modern medicine thinks that urticarial pathogenesis is comparatively complicated, so far still for getting clear fully, it is generally acknowledged that most of acute urticarias are the I allergic reaction type.Cause because mastocyte discharges histamine, cause telangiectasis, permeability increases, and plasma protein enters corium in a large number, shows as welt or localized edema clinically.Doctor trained in Western medicine based on antiallergic, does not still have definite curative effect to urticarial treatment.
Skin pruritus is a kind of conscious skin pruritus and do not have the dermatosis of primary lesion, and its pathogeny is not clear so far, and the traditional Chinese medical science thinks to be asthenia of essence and blood, due to the wind syndrome due to blood-deficiency, or be skin blood operation sluggishness, hematogenous blockage, ailment said due to cold or exposure is attacked the people, invades and skin, and is strongly fragrant due to the lung meridian.Can be divided into general skin pruritus and limitation skin pruritus clinically.It is more that the old people suffers from this sick chance.Doctor trained in Western medicine based on antiallergic, does not still have definite curative effect to the treatment of skin pruritus.
Theory of Chinese medical science thinks that dermatosis and ailment said due to cold or exposure are closely related, meets the characteristics of " wind being the primary exopathogen, benefaction and number become ".No matter the patient is because of internal injury caused by excess of seven emotions, the body imbalance of YIN and YANG, and battalion defends and becomes estranged, and weakened defensive QI is felt ailment said due to cold or exposure again and is sent out, or because of the thing of surfeit greasy and surfeit flavour, meat or fish wind symptom, and damp-heat in the spleen and stomach is felt ailment said due to cold or exposure again and is sent out; Or weak usually, deficiency of YIN-blood, the deficiency of YIN is given birth to interior-heat, wind syndrome due to blood-deficiency; Or outbreak repeatedly, QI and blood is consumed, and ailment said due to cold or exposure is attacked and is caused.
There are many doctors to adopt the acute and chronic urticaria of traditional Chinese medical herbal treatment clinically, obtained curative effect preferably.As Feng Xia (" Chinese skin cypridology magazine ", 2004,1:52) with Chinese medicine angelica a decotion of Chinese medicine to be taken cold treatment chronic urticaria 90 examples, wherein 60 examples are organized in treatment, loratadine matched group 30 examples.The treatment group gives Radix Angelicae Sinensis a decotion of Chinese medicine to be taken cold (Radix Angelicae Sinensis, the Radix Polygoni Multiflori, the Radix Paeoniae Alba, Herba Schizonepetae, Radix Saposhnikoviae, the Radix Rehmanniae, Fructus Tribuli, Rhizoma Chuanxiong, the Radix Astragali, Radix Glycyrrhizae) and is decocted in water for oral dose, obey every day 2 times, the oral loratadine tablet 10mg of matched group, inferior every night, took for 4 weeks continuously and carry out efficacy evaluation, treatment group total effective rate is 93.33%, and the matched group total effective rate is 73.33%, two groups of curative effects relatively have statistical significance, P＜0.05.Late result compares, i.e. drug withdrawal is after 3 months, and treatment group relapse rate is 22.58%, and matched group is that 61.53%, two group of relapse rate relatively has statistical significance, P＜0.05.
Treatment for skin pruritus, the most frequently used method is an external washout with traditional Chinese herbs, as Song Guangying (" Shandong Traditional Chinese Medicine University's journal ", 2004,28 (6): 479) treat 174 routine skin prurituss with embathing the affected part after diffusing (Radix Sophorae Flavescentis, Cortex Phellodendri, Rhizoma Coptidis, Pericarpium Granati, Mahonia fortunei (Lindl.) Fedde, Herba Hieracii Umbellati, the Fructus Kochiae, Radix Sanguisorbae) boiled water immersion of easypro skin, and set up matched group 111 examples to be made into 20: 5000 concentration solution washouts, every day 2 times with lysol and warm water.Skin pruritus shape disappearance person treatment group is 174 examples (100%) in the 10d as a result, and matched group is 78 examples (70.27%).
Though for many years the treatment research of urticaria and skin pruritus is subjected to the attention of Chinese medicine researcher, but the new Chinese medicine that is developed into seldom, and Western medicine is a relief of symptoms, and more untoward reaction is arranged, so still need to be the clinical safe and effective medicine more that provides.The present inventor sums up from clinical experience for many years and constantly weighs, and modification and perfection has been finished the present invention repeatedly.
Summary of the invention
Purpose of the present invention aims to provide low, the eutherapeutic Chinese medicine composition that is used for the treatment of urticaria and skin pruritus of a kind of side effect.
Another object of the present invention is to provide the preparation method of this Chinese medicine composition.
Based on theory of Chinese medical science to urticaria and pathogenetic understanding of skin pruritus and Therapeutic Principle, achieve with reference to modern pharmacological research, the Herba Spirodelae that the present invention selects has relieving the exterior syndrome by diaphoresis, rash, dispelling wind for relieving itching, removing pathogenic heat from blood and toxic substance from the body, diuretic and cuts bullate effect, very light blue have a relieving the exterior syndrome by diaphoresis, sharp key activates yang, warming middle-JIAO to promote flow of QI, the effect of removing toxic substances and promoting subsidence of swelling.The modern pharmacology effect of above single medicinal material is one of foundation of prescription, also is the important pharmacodynamics basis of clinical efficacy.
Chinese medicine composition of the present invention is with Herba Spirodelae and very light blue as effective ingredient, is equipped with pharmaceutically acceptable carrier and makes.Its contained active ingredient raw materials is by weight percentage: Herba Spirodelae 25%～75%, very light blue 25%～75%.Preferred Herba Spirodelae 35%～65%, very light blue 35%～65%.More preferably Herba Spirodelae 50%, and very light blue 50%.
The preparation method of Chinese medicine composition of the present invention, it comprises: with Herba Spirodelae and very light blue decocting together, filter, obtain the water extract of above-mentioned raw materials; Perhaps above-mentioned raw material of Chinese medicine one is reinstated 50～95% alcohol reflux, reclaim ethanol and make ethanol extract; Perhaps with Herba Spirodelae with 50～95% alcohol reflux, reuse water extraction behind the very light blue extraction volatile oil concentrates back and the merging of very light blue volatile oil with the two extracting solution; Perhaps with Herba Spirodelae with 50～95% alcohol reflux, behind the very light blue extraction volatile oil gained medicinal residues with the medicinal residues reuse water extraction of Herba Spirodelae, with water guide and support, the Herba Spirodelae ethanol extract concentrates the very light blue volatile oil in back and merges.
Chinese medicine composition of the present invention can be made various common formulations together with its effective ingredient and/or acceptable accessories, as granule, capsule, drop pill, soft capsule, effervescent tablet, oral liquid, tablet, pill and coated pill.
Chinese medicine composition of the present invention has the function of dispelling wind to relieve the exterior syndrome, lung qi dispersing cold expelling, can be used for treating acute and chronic urticaria and skin pruritus, and safe and effective.
The routine clinical consumption of Chinese medicine composition of the present invention: be equivalent to 0.85g crude drug/kg body weight every day.
The specific embodiment
Can further be expressly understood the present invention by specific embodiments of the invention given below, but following embodiment not a limitation of the invention.
Embodiment 1
Get Herba Spirodelae 25g, very light blue 75g, add 1000ml 50% ethanol, reflux 3 times, each 0.5 hour, merge extractive liquid, filtered, and filtrate decompression is concentrated into relative density 1.11～1.13 (50 ℃), and spray drying adds an amount of lactose, and mixing is made granule.The aluminum-plastic composite membrane packing, promptly.
Embodiment 2
Get Herba Spirodelae 35g, very light blue 65g equivalent, add 900ml 70% ethanol, reflux 3 times, each 0.5 hour, merge extractive liquid,, filter, filtrate decompression is concentrated into relative density 1.11～1.13 (50 ℃), and spray drying adds an amount of lactose, mixing is made granule, incapsulates, and bottling, promptly.
Embodiment 3
Herba Spirodelae 40g adds 400ml 80% alcohol reflux 2 times, each 1 hour, decompression recycling ethanol.The very light blue extraction volatile oil of 60g, medicinal residues added the 800ml decocting in water 1 hour again with the Herba Spirodelae medicinal residues, and merged concentrating under reduced pressure with the water liquid of Extraction oil, Herba Spirodelae and very light blue two parts concentrated solution are merged macroporous resin adsorption, the purification removal of impurity, drop pill is made in cold preservation, bottling, promptly.
Embodiment 4
Herba Spirodelae 40g adds 400ml 80% alcohol reflux 2 times, and each 1 hour, decompression recycling ethanol, the very light blue extraction volatile oil of 50g, medicinal residues add the steaming and decocting of 400ml water once again, merge 2 times water liquid.With Herba Spirodelae and very light blue two parts concentrated solution merging, volatile oil is added concentrating under reduced pressure, spray drying is ground into powder, and the ' Yanming ' capsules for clearing of packing into is made soft capsule, bottling, promptly.
Embodiment 5
Herba Spirodelae 45g adds 360ml 95% alcohol reflux 2 times, and each 1 hour, decompression recycling ethanol, the very light blue extraction volatile oil of 55g, medicinal residues add 550ml times of water gaging steaming and decocting once again, merge 2 times water liquid.With Herba Spirodelae and very light blue two parts concentrated solution merging, volatile oil is added concentrating under reduced pressure, spray drying is ground into powder, and with an amount of excipient, the lytic agent mix homogeneously is made effervescent tablet, packing, promptly.
Embodiment 6
Get Herba Spirodelae, very light blue each 50g, add 1200ml times of water, steaming and decocting 30 minutes is steamed 2 times, is evaporated to relative density, and 1.06～1.08, cold preservation 24 hours filters, decolouring, it is heavy to remove, and adds an amount of lactose, and Mel and water are made oral liquid, bottling, packing, promptly.
Embodiment 7
Get Herba Spirodelae, very light blue each 50g adds 1000ml times of water, steaming and decocting 30 minutes is steamed 2 times, is evaporated to relative density, 1.06～1.08, cold preservation 24 hours filters, spray drying is ground into powder, and is even with an amount of mixed with excipients, tabletting, bottling promptly.
Embodiment 8
Get Herba Spirodelae, very light blue each 50g, add 1000ml times of water, steaming and decocting 30 minutes is steamed 2 times, is evaporated to relative density, 1.06～1.08, cold preservation 24 hours filters, spray drying is ground into powder, even with an amount of mixed with excipients, make pill, coating is made coated pill, and bottling is promptly.
Below by pharmacodynamics and toxicological experiment the present invention is further set forth.
Medicine: the granule of spray-dried gained in the embodiments of the invention 1 or 2, add aseptic drinking water be mixed with variable concentrations for the reagent thing, below in each experimental example for reagent concentration all in " g crude drug/kg body weight ".
Animal: be the SPF/VAF level.
Experimental example 1: rat passive cutaneous anaphylaxis test of the same race
50 of 200～220g SD rats are divided into matched group at random, hismanal 1.3mg/kg group, for reagent 8.0g/kg group, 4.0g/kg group and 2.0g/kg group, every group of 10 animals.Successive administration 7 days.In the time of the 3rd day the rat back hair is shaved only.Serum by dilution in 1: 1,1: 5,1: 10, and by different dilution serum order, gives every to be injected in each point after shaving hair through Intradermal through normal saline.Carry out antigen behind the 48h and attack, intravenous injection 0.5% azovan blue oralbumin solution 1ml takes off cervical vertebra and puts to death animal behind the 20min.Bark fetching detects diameter of each blue reaction speckle, and institute's data of surveying are checked the comparable group differences through t.
The result: dilution factor sensitization serum after show good anti-allergic effects for reagent 8.0g/kg group at 1: 1 in injection, comparing with matched group is significant difference, P＜0.05, when 1: 5 and 1: 10 dilution factor effect not remarkable, P value is equal＞0.05; 4.0g/kg group and 2.0g/kg group do not demonstrate anti-allergic effects.
Table 1 Chinese medicine composition of the present invention is to the influence of rat models of passive skin irritability of the same race (cm X ± SD)
| Group | ??n | Dosage g/kg | Spot diameter (cm) | ||
| ??1∶1 | ????1∶5 | ????1∶10 | |||
| Matched group | ??9 | ??9.33±2.83 | ????3.11±3.41 | ????0.44±1.33 | |
| The hismanal group | ??11 | ????1.3mg | ??3.09±2.26 ** | ????0.82±1.94 | ????0.00±0.00 |
| For reagent 1 | ??10 | ????8.0 | ??6.71±2.11 * | ????1.80±2.10 | ????0.20±0.63 |
| For reagent 2 | ??9 | ????4.0 | ??7.11±3.06 | ????3.44±3.13 | ????1.00±2.35 |
| For reagent 3 | ??10 | ????2.0 | ??7.90±2.13 | ????1.80±2.94 | ????1.10±2.33 |
Compare with matched group
*P＜0.01
*P＜0.05
Experimental example 2: mouse DTH allergy test
Select 60 of 20～22g ICR mices for use, male and female half and half are divided into the blank group at random, model group, and dexamethasone 1.0mg/kg group is for executing the 8.0g/kg group, 4.0g/kg group and 2.0g/kg group, every group of 10 animals.Except that matched group, other animals with 5%2,4-dinitrochlorobenzene acetone soln is applied to abdominal part sensitization, sensitization begins administration on the same day, once a day, continuous 14 days.Sensitization 2 week the back with 1%2,4-dinitrochlorobenzene acetone soln is applied to mouse right ear portion and attacks, and puts to death animal after 24 hours, is the delayed hypersensitivity value with the difference of left and right sides ear weight.The data of surveying through t check comparable group differences.
The result: experimental data shows, through 1%2, after 4-dinitrochlorobenzene acetone soln attacks, two indexs of model group mice auricle swelling degree and thymic weight are compared with the blank group notable difference is all arranged, and the P value distinguishes＜0.01 and＜0.05, the model establishment.For reagent 8.0g/kg group to 2, the allergy of 4-dinitrochlorobenzene induced mice auricle has obvious inhibitory action, two indexs of swelling degree and thymic weight are compared with model group and all are significant difference, the P value distinguishes＜0.05,＜0.01 and＜0.05; 4.0g/kg and the effect of 2.0g/kg group inhibition mice auricle swelling is not obvious, but thymic weight is all shown good action.
Table 2 Chinese medicine composition of the present invention is to the influence of mouse DTH allergy (mg X ± SD)
| Group | ??n | Dosage g/kg | Left side ear heavy (mg) | Auris dextra heavy (mg) | Swelling degree (mg) | Suppression ratio (%) |
| Blank | ??10 | ??8.39±0.53 | ??9.20±0.74 | ??0.81±0.45 | ????- | |
| The model contrast | ??10 | ??- | ??8.00±0.68 | ??10.00±0.96 | ??2.08±0.16▲▲ | ????- |
| Dexamethasone | ??10 | ??1.0mg | ??6.48±0.42 ** | ??7.28±0.47 ** | ??0.80±0.19 ** | ????61.54 |
| For reagent 1 | ??10 | ??8.0 | ??7.67±0.63 | ??9.19±0.88 | ??1.42±0.33 * | ????31.73 |
| For reagent 2 | ??9 | ??4.0 | ??8.22±0.55 | ??10.48±1.94 | ??1.76±1.06 | ????15.38 |
| For reagent 3 | ??10 | ??2.0 | ??7.65±0.69 | ??9.56±1.38 | ??1.91±1.10 | ????8.17 |
Compare with the blank group ▲ ▲ P＜0.01; Compare with model control group
*P＜0.01
*P＜0.05
Experimental example 3: rabbit Arthus reaction (III allergic reaction type) test
Get 36 of 2.0～2.5kg rabbit, be divided into the blank group at random, model control group, hismanal 0.6mgkg
-1Group, for reagent 4.0g/kg group, 2.0g/kg group and 1.0g/kg group, 6 every group.Weekly Freund ' s Freund's complete adjuvant the 1.0ml that contains oralbumin through intramuscular injection once, continuous 4 weeks, blank group injection equal-volume normal saline.Began gastric infusion the same day in the last injection, every day 1 time, continuous 10 days, blank and model group gavaged the aseptic drinking water of equal-volume.The 10th day through back intradermal injection 1% oralbumin solution 0.2ml with the back depilation in the 9th day.Record antigen is attacked the maximum gauge and the extent of reaction of back 2,3,4,6,8,24h local skin redness.
The result is as shown in table 3: model group is attacked at antigen and was occurred obvious pimple and erythema in back 2 hours, changes in time and increases the weight of gradually, reaches the peak in 8 hours, erythema is darkviolet, red, the swollen degree of each time period utmost point significant difference of having compared with the blank group, P value is equal＜and 0.01, the model establishment.Attack back 4 hour meters for reagent 4.0g/kg group at antigen and reveal better inhibitory action, comparing with model control group has significant difference, and the P value all＜0.05; Antigen was attacked after 24 hours, and comparing with model control group for the edema diameter of large, medium and small three the dosage groups of reagent has significant difference, P value difference＜0.05,＜0.01,＜0.01; Three dosage groups are all not obvious to the influence of erythema.
Table 3. Chinese medicine composition of the present invention is to the influence of rabbit III allergic reaction type (X ± SD)
| Group | Dosage gkg -1 | ?n | Edema diameter (cm) | |||||
| ??2h | ??3h | ??4h | ??6h | ??8h | ??24h | |||
| Blank | ??- | ?6 | ??0.00±0.00 | ??0.00±0.00 | ??0.00±0.00 | ??0.00±0.00 | ??0.00±0.00 | ??0.00±0.00 |
| The model contrast | ??- | ?6 | ??1.48± ????0.16▲▲ | ??1.80± ????0.22▲▲ | ??2.30± ????0.42▲▲ | ??2.58± ????0.47▲▲ | ??2.98± ????0.67▲▲ | ??4.67± ????0.44▲▲ |
| The hismanal group | ??0.6mg | ?6 | ??1.33±0.20 | ??1.37±0.12 ** | ??1.93±0.40 | ??1.88±0.23 * | ??2.50±0.34 | ??2.92±0.71 ** |
| For reagent 1 | ??4.0 | ?6 | ??1.45±0.16 | ??1.53±0.21 | ??1.70±0.19 * | ??2.26±0.17 | ??2.77±0.37 | ??3.87±0.56 * |
| For reagent 2 | ??2.0 | ?6 | ??1.40±0.34 | ??1.53±0.37 | ??2.00±0.13 | ??2.25±0.15 | ??2.67±0.60 | ??3.13±0.46 ** |
| For reagent 3 | ??1.0 | ?6 | ??1.40±0.28 | ??1.57±0.14 | ??1.95±0.20 | ??2.25±0.28 | ??2.62±0.31 | ??3.13±0.86 ** |
Compare with the blank group ▲ ▲ P＜0.01; Compare with model control group
*P＜0.01
*P＜0.05
Experimental example 4: irritated dielectric testing
60 of 150～200g SD rats are divided into the blank group at random, model group, the positive drug group, for reagent 8.0g/kg group, 4.0g/kg and 2.0g/kg organize every group of 10 animals.Successive administration 5 days.In the time of the 3rd day the rat back hair is shaved only.Inject 0.1ml histamine phosphate's solution (containing 50～100 μ g of histamine) to every except that the blank group through Intradermal, the blank group is injected isopyknic normal saline.The 0.5% diazo blue oralbumin solution 1ml of intravenous injection simultaneously takes off cervical vertebra and puts to death animal behind the 20min, bark fetching detects each blue diameter that reacts speckle; The data of surveying through t check comparable group differences.
The result: as shown in table 3, each dosage group does not all show the antagonism to histamine.
Table 4 Chinese medicine composition of the present invention is crossed the influence (X ± SD) of sensitive media to rat
| Group | ??n | Dosage (g/kg) | Spot diameter (gm) |
| Blank | ??10 | ??4.80±1.69 | |
| Histamine's group | ??10 | ????100μg | ??8.30±1.89▲▲ |
| The hismanal group | ??9 | ????1.3mg | ??3.78±1.30 ** |
| For reagent 1 | ??10 | ????8.0 | ??10.20±3.61 |
| For reagent 2 | ??10 | ????4.0 | ??12.60±1.89 |
| For reagent 3 | ??10 | ????2.0 | ??8.10±4.41 |
Compare with the blank group ▲ ▲ P＜0.01; Compare with model control group
*P＜0.01
Experimental example 5: histamine causes the test of Cavia porcellus pruritus
50 body weight are divided into blank group, positive drug group at random 300～350g Cavia porcellus, reach the group for reagent 8.0g/kg, 4.g/kg group and 2.0gkg group.Gastric infusion is 7 days continuously, and matched group gavages the aseptic drinking water of equal-volume.Test the last hair of shaving right back instep of saying, the last administration abraded instep 1cm2 with sand paper after 1 hour, drip the 0.01% solution 0.05ml/ of histamine phosphate on the instep only, after this per 3 minutes according to 0.01%, 0.02%, 0.03% ... progressive concentration, each 0.05ml/ only, when occurring licking foot phenomenon till.The histamine phosphate's total amount that is given when occurring licking foot phenomenon is for causing the value of itching, record and with t check comparable group differences.
Table 5 the present invention is to Cavia porcellus itching relieving influence (X ± SD)
| Group | ??n | Dosage (g/kg) | Histamine's consumption (mg) |
| Matched group | ??10 | ??- | ??0.46±0.12 |
| The hismanal group | ??10 | ??1.3mg | ??0.82±0.26 ** |
| For reagent 1 | ??10 | ??8.0 | ??0.97±0.07 ** |
| For reagent 2 | ??10 | ??4.0 | ??0.67±0.22 * |
| For reagent 3 | ??10 | ??2.0 | ??0.79±0.24 ** |
Compare with matched group
*P＜0.01
*P＜0.05
Experimental example 6: mice caused by dimethylbenzene xylene auricle acute inflammation test
Selective body focuses on 50 of 20～22g ICR male mices.Animal is divided into blank group, positive controls at random, organizes for reagent 12.0g/kg, 6.0g/kg group and 3.0g/kg group, 10 every group.Continuous oral administration 7 days, the oral isopyknic aseptic drinking water of blank group, smear dimethylbenzene 0.05ml for after 1 hour the two sides of every mouse right ear in the last administration, card punch with diameter 6mm after 30 minutes is laid auricle at the same position of mice left and right sides ear, weigh immediately, with about the difference of two auricle weight be the swelling degree, calculate swelling rate and suppression ratio, through t check comparable group differences.
The result: result of the test shows, for reagent 12.0g/kg group mouse right ear swelling degree and the swelling rate significant difference of having compared with matched group, the P value is equal＜and 0.05; 6.0g/kg the swelling rate of group mouse right ear is compared with matched group and is significant difference, P＜0.05, and the swelling degree does not demonstrate significant difference because of standard deviation is bigger than normal; 3.0g/kg group does not show this effect.
Table 6 xylol of the present invention causes the acutely inflamed influence of Mice Auricle (X ± SD)
| Group | ??n | Dosage g/kg | Left side ear heavy (mg) | Auris dextra heavy (mg) | Swelling degree (mg) | Swelling rate (%) | Suppression ratio (%) |
| Matched group | ??10 | ??- | ??8.77±0.57 | ??19.05±2.74 | ??10.28±2.78 | ??118.01±34.48 | ??- |
| Dexamethasone group | ??10 | ??1.0mg | ??7.85±0.41 ** | ??11.51±2.52 ** | ??3.66±2.51 ** | ??46.78±32.10 ** | ??60.36 |
| For reagent 1 | ??10 | ??12.0 | ??9.06±0.43 | ??16.60±2.38 * | ??7.54±2.54 * | ??83.91±30.37 * | ??28.90 |
| For reagent 2 | ??10 | ??6.0 | ??924±0.62 | ??16.73±3.11 | ??7.49±3.04 | ??81.36±32.62 * | ??31.06 |
| For reagent 3 | ??10 | ??3.0 | ??9.24±039 | ??21.06±3.55 | ??11.82±3.82 | ??129.29±44.85 | ??-9.56 |
Compare with matched group
*P＜0.01
*P＜0.05
Experimental example 7: to the influence test of normal mouse autonomic activities
Select 150 of the female mices of body weight 20～22g.Be divided into big group of 3 times at random by body weight, big group of each time is further divided into matched group, diazepam group, for reagent 12.0g/kg, three dosage groups of 6.0g/kg and 3.0g/kg, 10 every group.Every mouse stomach is administered once.After 1 hour, 2 hours, 4 hours mice is put into mice autonomic activities instrument by the Latin square order respectively at administration, write down mice autonomic activities number of times in 5 minutes.Compare with the blank group, carry out statistical calculations.
Table 7 the present invention is to the influence of normal mouse autonomic activities (X ± SD)
| Group | Dosage g/kg | The autonomic activities number of times | |||||
| ??n | ??1h | ??n | ??2h | ??n | ??4h | ||
| Matched group | ??- | ??10 | ??306.20±128.34 | ??10 | ??305.50±68.59 | ??10 | ??281.90±38.85 |
| The diazepam group | ??2.0mg | ??10 | ??180.90±102.82 * | ??10 | ??230.90±70.05 * | ??10 | ??265.60±97.29 |
| For reagent 1 | ??12.0 | ??10 | ??259.60±102.66 | ??10 | ??298.40±71.17 | ??10 | ??325.90±55.81 |
| For reagent 2 | ??6.0 | ??10 | ??270.10±81.52 | ??10 | ??275.00±61.14 | ??10 | ??275.80±39.92 |
| For reagent 3 | ??3.0 | ??10 | ??282.10±61.11 | ??10 | ??277.10±59.10 | ??10 | ??323.80±77.77 |
Compare with matched group
*P＜0.01
*P＜0.05
Experimental example 8: acute toxicity testing
Get 40 of ICR kind mices, male and female half and half, after irritating stomach twice in the 128.0g/kg (be equivalent to clinical dosage 150.6 times) a day, continuation through 2 weeks is observed, removing administration group male mice body weight decreases, the significant difference of having compared with the blank group outer (P＜0.05), all other indexs there is no unusually, and do not have death.
Experimental example 9: long term toxicity test
Get 80 of SD rats, be divided at random for reagent 64.0g/kg group, 32.0g/kg group, 16.0g/kg group and normal control group, each 10 of every group of male and female by body weight.Every day, gastric infusion was 2 times, continuous 30 days.The oral isopyknic sterilising drinking water of blank group.Write down body weight, food ration weekly once, observe independent activity of animals, fur, feces situation every day.After the administration 1 month, get each 6 animal of male and female at random from every group respectively, get blood through socket of the eye clump vein, the test clotting time, hematological indices, serum biochemistry index, internal organs are weighed and calculate organ index, each organs and tissues is fixed with 10% neutral formalin, paraffin embedding, section, the HE normal dyeing, microscopically carries out histopathologic examination.All the other animals continue to raise for 2 weeks after drug withdrawal, repeat the inspection of above-mentioned project, observe the recovery situation of toxic reaction and have or not the toxic reaction that postpones appearance.
Every physical signs of each administration treated animal does not all occur because of drug-induced toxic reaction.Each internal organs of heavy dose of treated animal there is no the specific tissue form that causes because of dealed with medicine went and change the no significant difference of comparing with matched group.
Claims (8)
1, a kind of Chinese medicine composition that is used for the treatment of urticaria and skin pruritus, it is made up of effective ingredient and/or pharmaceutically acceptable carrier, it is characterized in that its contained active ingredient raw materials is by weight percentage: Herba Spirodelae 25%～75%, very light blue 25%～75%.
2, Chinese medicine composition according to claim 1, wherein active ingredient raw materials Herba Spirodelae and very light bluely be by weight percentage: Herba Spirodelae 35%～65%, very light blue 35%～65%.
3, Chinese medicine composition according to claim 1, wherein active ingredient raw materials Herba Spirodelae and very light bluely be by weight percentage: Herba Spirodelae 50%, very light blue 50%.
4, according to claim 1,2 or 3 described Chinese medicine compositions, it can be granule, capsule, drop pill, soft capsule, effervescent tablet, oral liquid, tablet, pill and coated pill.
5, according to the preparation method of claim 1,2 or 3 described Chinese medicine compositions, it comprises that the decocting that above-mentioned raw material of Chinese medicine one is reinstated 8～12 times of amounts (w/v, down with) boils, and filters, and obtains the water extract of above-mentioned raw materials.
6, according to the preparation method of claim 1,2 or 3 described Chinese medicine compositions, it comprises 50%～95% alcohol reflux of above-mentioned raw material of Chinese medicine one being reinstated 8～12 times of amounts, reclaims ethanol and makes ethanol extract.
7, according to the preparation method of claim 1,2 or 3 described Chinese medicine compositions, it comprises 50%～95% alcohol reflux of Herba Spirodelae with 8～12 times of amounts, the water extraction of 8～12 times of amounts of reuse behind the very light blue extraction volatile oil merges concentrated back of the extracting solution of the two and very light blue volatile oil.
8, according to the preparation method of claim 1,2 or 3 described Chinese medicine compositions, it comprises 50%～95% alcohol reflux of Herba Spirodelae with 8～12 times of amounts, the gained medicinal residues are with the water extraction of 8～12 times of amounts of medicinal residues reuse of Herba Spirodelae behind the very light blue extraction volatile oil, with water guide and support, the Herba Spirodelae ethanol extract concentrates the back and merges with very light blue volatile oil.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100122086A CN100344311C (en) | 2005-07-15 | 2005-07-15 | Chinese medicine composition for treating nettle-rash and skin itch and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100122086A CN100344311C (en) | 2005-07-15 | 2005-07-15 | Chinese medicine composition for treating nettle-rash and skin itch and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1709312A true CN1709312A (en) | 2005-12-21 |
| CN100344311C CN100344311C (en) | 2007-10-24 |
Family
ID=35705644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100122086A Active CN100344311C (en) | 2005-07-15 | 2005-07-15 | Chinese medicine composition for treating nettle-rash and skin itch and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100344311C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102462798A (en) * | 2010-11-18 | 2012-05-23 | 保定步长天浩制药有限公司 | Application of medicinal composition to preparation of medicament for treating viral influenza |
| CN102772597A (en) * | 2012-07-31 | 2012-11-14 | 王锦美 | Decoction medicine for treating internal-heat attacking lung type urticaria |
| CN106729488A (en) * | 2015-11-24 | 2017-05-31 | 哈尔滨墨医生物技术有限公司 | A kind of duckweed dispelling wind-heat lozenge and its production method |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1321669C (en) * | 2004-10-14 | 2007-06-20 | 李爱英 | Chinese herbal medicine for treating urticaria |
-
2005
- 2005-07-15 CN CNB2005100122086A patent/CN100344311C/en active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102462798A (en) * | 2010-11-18 | 2012-05-23 | 保定步长天浩制药有限公司 | Application of medicinal composition to preparation of medicament for treating viral influenza |
| CN102462798B (en) * | 2010-11-18 | 2013-06-12 | 保定步长天浩制药有限公司 | Application of medicinal composition to preparation of medicament for treating viral influenza |
| CN102772597A (en) * | 2012-07-31 | 2012-11-14 | 王锦美 | Decoction medicine for treating internal-heat attacking lung type urticaria |
| CN106729488A (en) * | 2015-11-24 | 2017-05-31 | 哈尔滨墨医生物技术有限公司 | A kind of duckweed dispelling wind-heat lozenge and its production method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100344311C (en) | 2007-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103263488B (en) | Chinese medicine fumigation-washing decoction for treating capecitabine extremities syndrome | |
| CN100344311C (en) | Chinese medicine composition for treating nettle-rash and skin itch and its preparing method | |
| CN104248722A (en) | Medicament for treating female hypersexuality | |
| CN101007159B (en) | Traditional Chinese medicine for preventing and controlling tumor | |
| CN102225118B (en) | Blood-activating wind-dispelling liquid | |
| CN104189781A (en) | Pharmaceutical composition for treating neuroglioma | |
| CN102940757A (en) | Medicine composition for treating diabetic foot | |
| CN104288597B (en) | A kind of Chinese medicine composition for treating herpes zoster | |
| CN103585596B (en) | Traditional Chinese medicine composition for treating migraine | |
| CN102908423A (en) | Chinese medicinal composition for treating stones | |
| CN105617198A (en) | Method for preparing medicinal liquor for treating wind-cold low back pain | |
| CN1330366C (en) | Piles ointment and its preparation method | |
| CN104645144A (en) | Traditional Chinese medicine preparation for treating nephritis and preparation method of traditional Chinese medicine preparation | |
| CN104248677A (en) | Traditional Chinese medicinal preparation for treating erythema multiforme | |
| CN102824608A (en) | Externally used Chinese herba preparation for treating peripheral vascular disease | |
| CN103028058B (en) | Traditional Chinese medicine composition for treating feebleness | |
| CN102784280A (en) | Traditional Chinese medicine fumigating and washing liquid for treating migraine | |
| CN110841007B (en) | Traditional Chinese medicine composition for treating cerebral apoplexy sequela and application thereof | |
| CN101983712A (en) | Novel medicament for treating coronary heart disease | |
| CN109806321B (en) | A Chinese medicinal composition, its preparation method and application in preparing medicine for treating trauma | |
| CN105663838A (en) | Traditional Chinese medicine for treating choledocholithiasis by combining epidural anesthesia and preparation method | |
| CN1679695A (en) | Chinese medicine preparation for treating bone fracture and preparing method thereof | |
| CN104161861A (en) | Traditional Chinese medicine for treating senile constipation | |
| CN105213985A (en) | A kind of Chinese medicine decoction for the treatment of syndrome of marrow depletion due to kidney deficiency type cranial tinnitus | |
| CN104666926A (en) | Hypertension improving agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BAODING BUCHANG TIANHAO PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: WANG ZHIMING Effective date: 20100528 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100021 207, BUILDING 26, PANJIAYUANNANLI, CHAOYANG DISTRICT, BEIJING TO: 072650 ARMY NO.86188, DINGXING COUNTY, HEBEI PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20100528 Address after: 072650 Hebei province Dingxing County 86188 army hospital Patentee after: Baoding Buchang Tianhao Pharmaceutical Co., Ltd. Address before: 100021, Beijing, Chaoyang District Panjiayuan South 26 floor, 207 Patentee before: Wang Zhiming |
|
| C56 | Change in the name or address of the patentee |
Owner name: BAODING TIANHAO PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: BAODING BUCHANG TIANHAO PHARMACEUTICAL CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: Xinghua 072650 Hebei province Dingxing County Road No. 128 Patentee after: BAODING TIANHAO PHARMACEUTICAL CO., LTD. Address before: 072650 Hebei province Dingxing County 86188 army hospital Patentee before: Baoding Buchang Tianhao Pharmaceutical Co., Ltd. |